Xencor Overview

  • Year Founded
  • 1997

Year Founded

  • Status
  • Public

  • Employees
  • 260

Employees

  • Stock Symbol
  • XNCR

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $34.04
  • (As of Thursday Closing)

Xencor General Information

Description

Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.

Contact Information

Website
xencor.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 465 North Halstead Street
  • Suite 200
  • Pasadena, CA 91107
  • United States
+1 (626)
Primary Industry
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 465 North Halstead Street
  • Suite 200
  • Pasadena, CA 91107
  • United States
+1 (626)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Xencor Stock Performance

As of 19-Nov-2026, Xencor’s stock price is $34.04. Its current market cap is $2.55B with 75M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$34.04 $34.39 $10.38 - $40.60 $2.55B 75M 1.53M -$1.56

Xencor Financials Summary

As of 30-Sep-2026, Xencor has a trailing 12-month revenue of $200M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 1,568,772 691,517 1,147,601 858,607
Revenue 200,494 125,576 110,493 174,615
EBITDA (103,574) (74,718) (218,103) (121,290)
Net Income (117,862) (91,923) (232,618) (133,133)
Total Assets 770,505 875,495 951,945 965,135
Total Debt 160,227 187,747 231,953 251,943
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Xencor Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Xencor‘s full profile, request access.

Request a free trial

Xencor Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Xencor‘s full profile, request access.

Request a free trial

Xencor Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody thera
Biotechnology
Pasadena, CA
260 As of 2025

Rockville, MD
 

San Diego, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Xencor Competitors (105)

One of Xencor’s 105 competitors is Macrogenics, a Formerly VC-backed company based in Rockville, MD.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Macrogenics Formerly VC-backed Rockville, MD
AnaptysBio Formerly VC-backed San Diego, CA
Genetix Biotherapeutics Private Equity-Backed Somerville, MA
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
MediGene Formerly VC-backed Planegg, Germany
You’re viewing 5 of 105 competitors. Get the full list »

Xencor Patents

Xencor Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026076317-A1 Bispecific antibodies that bind to mica/b and cd3 Pending 04-Oct-2024
US-20260209369-A1 Anti-tl1a x anti-il23 antibodies Pending 09-Sep-2024
WO-2026055669-A2 Anti-tl1a x anti-il23 antibodies Pending 09-Sep-2024
WO-2026055669-A3 Anti-tl1a x anti-il23 antibodies Pending 09-Sep-2024
US-20260070982-A1 Antigen binding molecules to cd3 and cd19 Pending 07-Sep-2024 A61P35/00
To view Xencor’s complete patent history, request access »

Xencor Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Xencor Investments (2)

Xencor’s most recent deal was a Early Stage VC with Zenas BioPharma for . The deal was made on 07-Nov-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Zenas BioPharma 07-Nov-2022 Early Stage VC Drug Discovery
Zenas BioPharma Early Stage VC Drug Discovery
To view Xencor’s complete investments history, request access »

Xencor ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

34.06 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Xencor’s complete esg history, request access »

Xencor Exits (2)

Xencor’s most recent exit was on 07-Nov-2022 from Zenas BioPharma. The exit was categorized as with 14 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Zenas BioPharma 07-Nov-2022 Completed
  • 14 buyers
Zenas BioPharma Early Stage VC Completed
  • 5 buyers
To view Xencor’s complete exits history, request access »

Xencor FAQs

  • When was Xencor founded?

    Xencor was founded in 1997.

  • Where is Xencor headquartered?

    Xencor is headquartered in Pasadena, CA.

  • What is the size of Xencor?

    Xencor has 260 total employees.

  • What industry is Xencor in?

    Xencor’s primary industry is Biotechnology.

  • Is Xencor a private or public company?

    Xencor is a Public company.

  • What is Xencor’s stock symbol?

    The ticker symbol for Xencor is XNCR.

  • What is the current stock price of Xencor?

    As of 19-Nov-2026 the stock price of Xencor is $34.04.

  • What is the current market cap of Xencor?

    The current market capitalization of Xencor is $2.55B.

  • What is Xencor’s current revenue?

    The trailing twelve month revenue for Xencor is $200M.

  • Who are Xencor’s competitors?

    Macrogenics, AnaptysBio, Genetix Biotherapeutics, Adaptimmune Therapeutics, and MediGene are some of the 105 competitors of Xencor.

  • What is Xencor’s annual earnings per share (EPS)?

    Xencor’s EPS for 12 months was -$1.56.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process